

**ASX ANNOUNCEMENT**

29 October 2020

**Patent Application for Next Generation wheezo Algorithm Filed**

**Respiri Limited (ASX:RSH) (“Respiri” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management, today announces the filing of an additional patent application based on improvements made to the wheezo™ algorithm over the last 6 months by the Company’s development team.

The additional Intellectual Property (IP) relates principally to a method of processing recordings of a subject’s breathing, whereby an analysis algorithm processes the sound signal and marks periods containing pitch that is characteristic of wheeze via the trachea while concurrently eliminating background noise, thereby delivering an improved level of detection, a standardised and reproducible measure of wheeze.

Using a current gold standard, ACQ5 (asthma control questionnaire 5), wheeze is one of the symptoms currently subjectively assessed by physicians based on patient recall and self-assessment which many independent epidemiological studies indicate are less than ideal in building an accurate patient profile. This questionnaire approach is used today because there are no tools available that allow for an objective assessment of the patient’s respiratory condition in the real world.

Mr Marjan Mikel, CEO and Managing Director of Respiri said “The significant improvement in the sensitivity and specificity of our device shown in recent clinical trials highlights the important enhancements made to our algorithm, which we believe confers a distinct commercial advantage worthy of additional IP protection. wheezo is the first asthma management device to show such a high correlation to stethoscope measurement of wheeze via the chest or back, which is the gold standard used by doctors to assess patients in the clinic. Protecting our commercial advantage is of paramount importance as we move into our commercial launch in Australia and over the next 12-24 months into the UK, Europe and the United States.”

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
 CEO & Managing Director  
 Respiri Limited  
 P: +61 408 462 873  
 E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
 Executive Chairman  
 Respiri Limited  
 P: +61 447 074 160  
 E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement dated 29 October 2020 has been authorised for release by the Board of Directors of Respiri Limited.*

**About Respiri Limited**

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental

factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to improve asthma management by extending care beyond the clinic. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit [www.respiri.co](http://www.respiri.co)

### **About wheezo**

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device records wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

™ wheezo is a trademark of Respiri Limited

### **Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.